TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24758776
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of lidocaine 50 mg/h (10 ml) IV
Study: 24758776
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline 10 ml/h both intravenously and intermittently intraperitoneal
Study: 22717420
Drug: T80/H25 SPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: T80/H25 SPC (telmisartan/hydrochlorothiazide 80/25 mg)
Study: 22717420
Drug: T80 (telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: T80 (telmisartan 40 mg)
Study: 20151774
Drug: Exenatide 5
Normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 5 microg twice a day (titrated to 10 microg twice a day)
Study: 20151774
Drug: Glibenclamide 2.5
Normalized name: glibenclamide 2.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 2.5 mg three times a day (titrated to 5 mg three times a day)
Study: 16230141
Drug: Intrarectal 100‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal 100‐mg diclofenac suppository 1 hour before biopsy
Study: 16230141
Drug: Glycerin suppository
Normalized name: Leader Pediatric Glycerin Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin suppository as placebo intrarectally 1 hour before biopsy
Study: 12399191
Drug: HBsAg/AS04 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg/AS04 vaccine
Study: 12399191
Drug: Established hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established hepatitis B vaccine
Study: 29641834
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rACC theta marker with clinical and demographic variables
Study: 24880442
Drug: Clobetasol propionate-neomycin-nystatin
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate-neomycin-nystatin cream (CP-NN)
Study: 17918748
Drug: Immunomodulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulation treatment
Study: 2057620
Drug: Intramuscular premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular premedication with 0.2 mg/kg of midazolam and 0.015 mg/kg of atropine
Study: 2057620
Drug: Intranasal premedication
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal premedication with 0.2 mg/kg of midazolam and 0.015 mg/kg of atropine
Study: 2057620
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Intramuscular and Intranasal)
Study: 24613032
Drug: Vabicaserin 200
Normalized name: Vabicaserin
DrugBank: Vabicaserin (DB12071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vabicaserin 200 mg/day
Study: 24613032
Drug: Vabicaserin 400
Normalized name: Vabicaserin
DrugBank: Vabicaserin (DB12071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vabicaserin 400 mg/day
Study: 20519076
Drug: Depsides salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depsides salts from salvia miltiorrhiza (DSM) 0.2 g intravenously daily for 2 weeks
Study: 17173661
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2b (1.5 microg/kg/week) with ribavirin (800-1000 mg daily) for 48 weeks for genotype 1 and 4, 24 weeks for other genotypes
Study: 2706173
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at L2/3 with 3 ml of plain 0.5% bupivacaine
Study: 2706173
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at L4/5 with 3 ml of plain 0.5% bupivacaine
Study: 351355
Drug: Dexchlorpheniramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexchlorpheniramine (4 mg/70 kg)
Study: 31925917
Drug: Long-pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-pulsed Nd:YAG 1064-nm laser treatment
Study: 31925917
Drug: Topical amorolfine
Normalized name: amorolfine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amorolfine nail lacquer alone
Study: 31925917
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (laser + amorolfine)
Study: 28873425
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IRS and OUT
Study: 28873425
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IRS and LLIN
Study: 28873425
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IRS and KOTAB
Study: 25502833
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVI) 0.5 mg with isovolemic hemodilution (IH)
Study: 21815991
Drug: Smooth neck
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth neck implant
Study: 21815991
Drug: Pre-implant augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-implant augmentation procedure
Study: 21261621
Drug: DFDBA +
Normalized name: DFBA
DrugBank: Difluprednate (DB06781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFDBA + omega‐3 polyunsaturated fatty acids + low‐dose aspirin
Study: 11106141
Drug: Gotu Kola
Normalized name: GOTU KOLA
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gotu Kola (12-g orally administered dose)
Study: 30409131
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose dexmedetomidine (1.0 μg/kg loading followed by 0.5 μg/kg/min infusion)
Study: 30409131
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose dexmedetomidine (0.5 μg/kg loading followed by 0.25 μg/kg/min infusion)
Study: 20818904
Drug: Neoadjuvant platinum‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant platinum‐based chemotherapy followed by interval debulking surgery
Study: 20818904
Drug: Primary debulking
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary debulking surgery followed by platinum‐based chemotherapy
Study: 19000553
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg, 8 mg, or 12 mg sustained-release tablets
Study: 19000553
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg in fed state
Study: 19000553
Drug: Fesoterodine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine at all doses
Study: 1856145
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of amikacin (15 mg/kg) given iv over 30 min
Study: 1856145
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tobramycin (4.5 mg/kg) given iv over 30 min
Study: 1856145
Drug: 24‐h continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24‐h continuous infusion of amikacin
Study: 1856145
Drug: 24‐h continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24‐h continuous infusion of tobramycin
Study: 1856145
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of amikacin (7.5 mg/kg)
Study: 1856145
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections of tobramycin (1.5 mg/kg)
Study: 1856145
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of amikacin
Study: 6343143
Drug: Cimetidine and
Normalized name: Cimetidine and sodium alginate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine and chlorpheniramine in combination
Study: 30468136
Drug: Mindfulness group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness group therapy (MGT)
Study: 30468136
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (mostly cognitive-behavioral therapy)
Study: 28767146
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (RW) 375 ml/d for 4 weeks
Study: 25602465
Drug: S‐CBT (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐CBT (standard cognitive‐behavioral treatment)
Study: 25602465
Drug: A‐CBT (culturally
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐CBT (culturally accommodated cognitive‐behavioral treatment)
Study: 24471459
Drug: Minoxidil 2%
Normalized name: MINOXIDIL 2% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil 2% lotion
Study: 19581463
Drug: Meropenem 10
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 10 mg/kg
Study: 19581463
Drug: Meropenem 20
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 20 mg/kg
Study: 19581463
Drug: Meropenem 40
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 40 mg/kg
Study: 19581463
Drug: 8-hour dosing
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-hour dosing interval
Study: 19581463
Drug: 12-hour dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour dosing interval
Study: 19581463
Drug: 0.5-hour infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-hour infusion time
Study: 19581463
Drug: 4-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-hour infusion time
Study: 8174828
Drug: Adrenergic blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic blockers (propranolol and phentolamine)
Study: 8174828
Drug: Stressful stimuli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stressful stimuli or adrenergic blockers
Study: 28323893
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training (3 weekly sessions of 35 minutes moderate intensity walking/running followed by 25 minutes strength training)
Study: 26152322
Drug: Hydrocortisone 10
Normalized name: hydrocortisone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 10 mg/d
Study: 26152322
Drug: Hydrocortisone 30
Normalized name: hydrocortisone 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 30 mg/d
Study: 26152322
Drug: Hydrocortisone therapies
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone therapies (10 mg/d and 30 mg/d)
Study: 18308788
Drug: Methylphenidate (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (mean dose: 14.7 mg; range: 10-30 mg)
Study: 16834582
Drug: Benson Relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benson Relaxation Technique (BRT) combined with medication
Study: 16834582
Drug: Only medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only medication (control group)
Study: 11709742
Drug: Dose-dense ADoc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense ADoc regimen (4 cycles of Doxorubicin 50 mg/m², Docetaxel 75 mg/m² i.v. day 1, q day 15 or 22; G-CSF day 3-15 only for the dose-dense schedule)
Study: 9821453
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum lithium levels (0.8‐1.0 mmol L‐1)
Study: 9821453
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum lithium levels (0.5‐0.8 mmol L‐1)
Study: 9821453
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (both high and low levels)
Study: 7815279
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin formulation (delivered volumes of 80-160 microL)
Study: 25724407
Drug: Oral palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral palonosetron (0.50 mg) with oral dexamethasone
Study: 25724407
Drug: IV palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV palonosetron (0.25 mg) with oral dexamethasone
Study: 25724407
Drug: Oral palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral palonosetron (0.50 mg)
Study: 25724407
Drug: IV palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV palonosetron (0.25 mg)
Study: 22020357
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + fluoxetine (≤80 mg/d of fluoxetine)
Study: 22020357
Drug: Clomipramine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine + fluoxetine (≤75 and ≤40 mg/d, respectively)
Study: 22020357
Drug: Quetiapine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine + fluoxetine (≤200 and ≤40 mg/d, respectively)
Study: 19635614
Drug: BZA 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZA 20 mg with CE 0.625 mg
Study: 19635614
Drug: BZA 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZA 40 mg with CE 0.45 mg
Study: 19635614
Drug: BZA 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZA 10 mg with CE 0.625 mg
Study: 16757491
Drug: Primary PCI
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary PCI with 300 mg loading dose of clopidogrel
Study: 15300231
Drug: Cyclosporine (CS)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CS) 3 mg/kg/day intravenously, with subsequent oral dosing
Study: 15300231
Drug: Cyclosporine (CS)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CS) plus Methotrexate (MTX) 15 mg/m2 on day 1, and 10 mg/m2 on days 3, 6, and 11
Study: 8138651
Drug: Intramuscular nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular nefopam
Study: 23897052
Drug: Oxiplex gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiplex gel (carboxymethylcellulose/polyethylene oxide gel) applied during surgery
Study: 10900154
Drug: Methotrexate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (5 mg/m(2)/week)
Study: 10900154
Drug: No immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunosuppressive treatment (Control)
Study: 1474534
Drug: Nabumetone (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (2000 mg/day)
Study: 22218138
Drug: Placebo (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intermittent ultrasound therapy)
Study: 16213926
Drug: Short-term immunotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term immunotherapy (STI) with molecular standardized allergens (ALK(7), n = 24) plus anti-allergic drugs
Study: 16213926
Drug: Anti-allergic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-allergic drugs alone (n = 24)
Study: 12145716
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (ABCD; 6 mg/kg/day)
Study: 12145716
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AmB; 1.0-1.5 mg/kg/day)
Study: 8379178
Drug: Systemic intravenous
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic intravenous infusions (SVI)
Study: 3510660
Drug: Ketoconazole, 200
Normalized name: Ketoconazole, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole, 200 mg twice daily for male partners
Study: 29168473
Drug: Yangxin Tongmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxin Tongmai Formula (YTF) administered orally for 60 days
Study: 25912854
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (clindamycin or first-generation cephalosporin) for 2 to 4 days followed by oral antibiotics for 20 to 30 days
Study: 25912854
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (clindamycin or first-generation cephalosporin)
Study: 20307730
Drug: 3.6 mL
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mL of 2% lidocaine with 1:100,000 epinephrine
Study: 14725657
Drug: Sclerosing foam
Normalized name: SCLEROSING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerosing foam (polidocanol 3% solution, 2.0 or 2.5 mL injection)
Study: 14725657
Drug: Sclerosing liquid
Normalized name: SCLEROSING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerosing liquid (polidocanol 3% solution, 2.0 or 2.5 mL injection)
Study: 30071830
Drug: Sports Stars
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports Stars intervention (eight, one-hour, weekly physiotherapy group sessions)
Study: 26443600
Drug: Gel-filling technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-filling technique (GF)
Study: 24845165
Drug: Buprenorphine taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine taper (4-week duration)
Study: 21169166
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (n = 88)
Study: 21169166
Drug: Internet-based problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based problem-solving therapy (n = 88)
Study: 16173650
Drug: Ramelteon (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (16 mg)
Study: 16173650
Drug: Ramelteon (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (64 mg)
Study: 16173650
Drug: Ramelteon (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (16 or 64 mg)
Study: 12930012
Drug: Actifed DM
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Actifed DM plus paracetamol (ADM/P group)
Study: 31138731
Drug: Clenil pressurized
Normalized name: Clenia
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenil pressurized metered‐dose inhaler (pMDI; 250 μg) with spacer
Study: 31138731
Drug: Qvar Easi‐Breathe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qvar Easi‐Breathe inhaler (100 μg) with spacer
Study: 29228091
Drug: nab-paclitaxel 150
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 150 mg/m2 days 1 and 15 Q28 (arm A)
Study: 29228091
Drug: nab-paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 100 mg/m2 days 1, 8 and 15 Q28 (arm B)
Study: 29228091
Drug: nab-paclitaxel 75
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 75 mg/m2 days 1, 8, 15 and 22 Q28 (arm C)
Study: 22492249
Drug: New gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: New gel medical device (Proctoial) containing hyaluronic acid, tea tree oil, and methyl-sulfonyl-methane
Study: 21416034
Drug: Community intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community intervention training health workers to train community-based women groups in recognizing malaria symptoms and providing first-line treatment.
Study: 17040305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OND and MET
Study: 17040305
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with OND, MET, and DEX
Study: 12968984
Drug: Omapatrilat 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 2.5 mg (single dose)
Study: 12968984
Drug: Omapatrilat (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (multiple doses: 10, 25, 50, 75, or 125 mg daily for 10 days)
Study: 12968984
Drug: Omapatrilat (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (single dose)
Study: 12968984
Drug: Omapatrilat (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (single and multiple doses)
Study: 12968984
Drug: Omapatrilat (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (multiple doses)
Study: 12968984
Drug: Omapatrilat (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (doses > 7.5 mg)
Study: 9760791
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (Tilade-8 mg/24 hours)
Study: 3838321
Drug: Minocycline hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline hydrochloride with iron (300 mg ferrous sulfate)
Study: 3838321
Drug: Tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline hydrochloride with iron (300 mg ferrous sulfate)
Study: 25824259
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin (0.5%) administered as one drop four times at 15-minute intervals starting 75 minutes before surgery.
Study: 25824259
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin (400 mg) administered as a single tablet 12 hours before surgery.
Study: 21346614
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg/d)
Study: 12126263
Drug: Moxonidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.6 mg o.d.
Study: 9651560
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g cholestyramine and 20 mg pravastatin
Study: 2693326
Drug: Combined endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined endocrine therapy (Tamoxifen with prednisolone or androgens)
Study: 342319
Drug: 7 log
Normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 log EID50/dose
Study: 342319
Drug: 6 log
Normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 log EID50/dose